Rui Yamaguchi

Rui Yamaguchi

Auto-generated profile, based on publicly available information

Rui Yamaguchi

Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Science
Verified
Journal Article
Closed access
PDF file
YJYoshikazu Johmura
Yoshikazu Johmura
TYTakehiro Yamanaka
Takehiro Yamanaka
SOSatotaka Omori
Satotaka Omori
TWTeh-Wei Wang
Teh-Wei Wang
Yuki SugiuraYuki Sugiura
Yuki Sugiura
MNMakoto Nakanishi
Makoto Nakanishi
Selective destruction of senescent cells: Senescent cells are associated with a variety of age-related medical conditions and thus have been proposed as potential targets for therapy, but we do not yet have a full understanding of the underlying mechanisms. Johmura et al. used RNA interference to screen for enzymes essential to the survival of senescent cells (see the Perspective by Pan and Locasale). The authors identified a key role for glutamine metabolism, particularly the enzyme glutaminase 1, and demonstrated that inhibition of this pathway induced the death of senescent cells. Glutaminase targeting also ameliorated aging-related organ dysfunction and obesity-related disorders in mouse models, suggesting the potential therapeutic value of this approach. Science , this issue p. 265 ; see also p. 234

30 August 2007 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
AFAndré Fujita
André Fujita
JSJoão R Sato
João R Sato
Miguel Miguel Garay MalpartidaMiguel Miguel Garay Malpartida
Miguel Miguel Garay Malpartida
RYRui Yamaguchi
Rui Yamaguchi
SMSatoru Miyano
Satoru Miyano
CFCarlos Ferreira
Carlos Ferreira
Background: To understand the molecular mechanisms underlying important biological processes, a detailed description of the gene products networks involved is required. In order to define and understand such molecular networks, some statistical methods are proposed in the literature to estimate gene regulatory networks from time-series microarray data. However, several problems still need to be overcome. Firstly, information flow need to be inferred, in addition to the correlation between genes. Secondly, we usually try to identify large networks from a large number of genes (parameters) originating from a smaller number of microarray experiments (samples). Due to this situation, which is rather frequent in Bioinformatics, it is difficult to perform statistical tests using methods that model large gene-gene networks. In addition, most of the models are based on dimension reduction using clustering techniques, therefore, the resulting network is not a gene-gene network but a module-module network. Here, we present the Sparse Vector Autoregressive model as a solution to these problems.Results: We have applied the Sparse Vector Autoregressive model to estimate gene regulatory networks based on gene expression profiles obtained from time-series microarray experiments. Through extensive simulations, by applying the SVAR method to artificial regulatory networks, we show that SVAR can infer true positive edges even under conditions in which the number of samples is smaller than the number of genes. Moreover, it is possible to control for false positives, a significant advantage when compared to other methods described in the literature, which are based on ranks or score functions. By applying SVAR to actual HeLa cell cycle gene expression data, we were able to identify well known transcription factor targets.Conclusion: The proposed SVAR method is able to model gene regulatory networks in frequent situations in which the number of samples is lower than the number of genes, making it possible to naturally infer partial Granger causalities without anya prioriinformation. In addition, we present a statistical test to control the false discovery rate, which was not previously possible using other gene regulatory network models.

28 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DMDaisuke Muraoka
Daisuke Muraoka
SNSEO Naohiro
SEO Naohiro
THTae Hayashi
Tae Hayashi
YTYoshiro Tahara
Yoshiro Tahara
KFKeisuke Fujii
Keisuke Fujii
HSHiroshi Shiku
Hiroshi Shiku
Immune checkpoint inhibitors and adoptive transfer of gene-engineered T cells have emerged as novel therapeutic modalities for hard-to-treat solid tumors; however, many patients are refractory to these immunotherapies, and the mechanisms underlying tumor immune resistance have not been fully elucidated. By comparing the tumor microenvironment of checkpoint inhibition–sensitive and –resistant murine solid tumors, we observed that the resistant tumors had low immunogenicity. We identified antigen presentation by CD11b+F4/80+ tumor–associated macrophages (TAMs) as a key factor correlated with immune resistance. In the resistant tumors, TAMs remained inactive and did not exert antigen-presenting activity. Targeted delivery of a long peptide antigen to TAMs by using a nano-sized hydrogel (nanogel) in the presence of a TLR agonist activated TAMs, induced their antigen-presenting activity, and thereby transformed the resistant tumors into tumors sensitive to adaptive immune responses such as adoptive transfer of tumor-specific T cell receptor–engineered T cells. These results indicate that the status and function of TAMs have a significant impact on tumor immune sensitivity and that manipulation of TAM functions would be an effective approach for improving the efficacy of immunotherapies.

5 June 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
YAyuta adachi
yuta adachi
RKRyo Kimura
Ryo Kimura
KHKentaro Hirade
Kentaro Hirade
SYShogo Yanase
Shogo Yanase
YNYuki Nishioka
Yuki Nishioka
HEHiromichi Ebi
Hiromichi Ebi

20 June 2019 in Blood
Verified
Journal Article
Closed access
PDF file
SNSousuke Nakamura
Sousuke Nakamura
KYKazuaki Yokoyama
Kazuaki Yokoyama
ESEigo Shimizu
Eigo Shimizu
NYNozomi Yusa
Nozomi Yusa
KKKanya Kondoh
Kanya Kondoh
ATArinobu Tojo
Arinobu Tojo
This study was performed to assess the utility of tumor-derived fragmentary DNA, or circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after undergoing myeloablative allogeneic stem cell transplantation (alloSCT). We retrospectively collected tumor and available matched serum samples at diagnosis and 1 and 3 months post-alloSCT from 53 patients with AML/MDS. After identifying driver mutations in 51 patients using next-generation sequencing, we designed at least one personalized digital-PCR assay per case. Diagnostic ctDNA and matched tumor DNA exhibited excellent correlations with variant allele frequencies. Sixteen patients relapsed after a median of 7 months post-alloSCT. Both mutation-persistence (MP) in bone marrow at 1 and 3 months post-alloSCT and corresponding ctDNA-persistence (CP) in the matched serum (MP1 and MP3; CP1 and CP3, respectively) were comparably associated with higher 3-year cumulative incidence of relapse rates [MP1 vs. non-MP1: 72.9% vs. 13.8% (P = 0.0012); CP1 vs. non-CP1: 65.6% vs. 9.0% (P = 0.0002); MP3 vs. non-MP3; 80% vs. 11.6% (P = 0.0002); CP3 vs. non-CP3: 71.4% vs. 8.4% (P < 0.0001)]. We subsequently evaluated whether subset analysis of patients with three genes associated with clonal hematopoiesis, DNMT3A, TET2, and ASXL1 (DTA), could also be helpful in relapse prediction. As a result, CP based on DTA gene mutations also had the prognostic effect on CIR. These results, for the first time, support the utility of ctDNA as a non-invasive prognostic biomarker in patients with AML/MDS, undergoing alloSCT. Key points Non-invasive testing of serum circulating tumor DNA (ctDNA) persistence post allogeneic transplant could predict relapse in AML and MDS. Predictive utility of testing ctDNA, including DNMT3A, TET2, and ASXL1, was comparable to that of mutation persistence in matched BM.

12 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMakoto Hirata
Makoto Hirata
NANaofumi Asano
Naofumi Asano
KKKotoe Katayama
Kotoe Katayama
AYAkihiko Yoshizawa
Akihiko Yoshizawa
YTYusuke Tsuda
Yusuke Tsuda
KMKoichi Matsuda
Koichi Matsuda
The genomic characteristics of dedifferentiated liposarcoma (DDLPS) that are associated with clinical features remain to be identified. Here, we conduct integrated whole exome and RNA sequencing analysis in 115 DDLPS tumors and perform comparative genomic analysis of well-differentiated and dedifferentiated components from eight DDLPS samples. Several somatic copy-number alterations (SCNAs), including the gain of 12q15, are identified as frequent genomic alterations. CTDSP1/2-DNM3OS fusion genes are identified in a subset of DDLPS tumors. Based on the association of SCNAs with clinical features, the DDLPS tumors are clustered into three groups. This clustering can predict the clinical outcome independently. The comparative analysis between well-differentiated and dedifferentiated components identify two categories of genomic alterations: shared alterations, associated with tumorigenesis, and dedifferentiated-specific alterations, associated with malignant transformation. This large-scale genomic analysis reveals the mechanisms underlying the development and progression of DDLPS and provides insights that could contribute to the refinement of DDLPS management.